B-cell depletion or belimumab or voclosporin for lupus nephritis?
Curr Opin Nephrol Hypertens
; 30(2): 237-244, 2021 03 01.
Article
en En
| MEDLINE
| ID: mdl-33186226
ABSTRACT
PURPOSE OF REVIEW Despite ground-breaking innovations for most autoimmune diseases, the treatment of lupus nephritis has remained largely the same for decades because none of the tested drugs demonstrated superiority over standard-of-care in randomized controlled clinical trials. RECENT FINDINGS:
Recently, the Belimumab in Subjects with Systemic Lupus Erythematosus - Lupus Nephritis trial tested belimumab, an inhibitor of B-cell activating factor, as an add-on therapy to steroids and either mycophenolate mofetil (MMF) or cyclophosphamide when given IV monthly over a period of 104 weeks at an effect size of 11% for a Primary Efficacy Renal Response. The NOBILITY trial reported positive results for the B-cell-depleting agent obinutuzumab as an add-on therapy to steroids and MMF when given IV every 6 months over a period of 76 weeks at an effect size of 22% for a complete renal response (CRR). The AURORA trial reported positive results for the calcineurin inhibitor voclosporin as an oral add-on therapy to low dose steroids and MMF when given twice daily over a period of 52 weeks at an effect size of 18.5% for a CRR.SUMMARY:
These studies will change the treatment landscape of lupus nephritis. In which way is discussed in this article.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Nefritis Lúpica
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Curr Opin Nephrol Hypertens
Asunto de la revista:
ANGIOLOGIA
/
NEFROLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Alemania